Prescribing exercise – the “miracle cure”

Latest articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Click the globe for translations.

EXi targets chronic illness with digital personalised platform for prescribing exercise.

British start-up EXi is making waves with its app for prescribing personalised activity programmes. The app provides programmes that address any combination of 23 health conditions, including diabetes, heart disease and depression.

A 12 week, 100 person clinical pilot study recently completed by EXi showed that the app was effective across a wide range of health metrics, including improvements in blood glucose levels, resting heart rate, blood pressure, abdominal circumference, BMI, 6-minute walk test and mood.

Longevity.Technology: Exercise is one of the few longevity therapies that has delivered proven results in humans. Indeed, a few years ago, the UK’s Academy of Medical Royal Colleges dubbed it “the miracle cure”. But knowing exactly what exercise to prescribe for an individual can be difficult and EXi is addressing this challenge head on. We caught up with the company’s co-founder and clinical director Carron Manning to find out more.

Manning, a chartered physiotherapist for more than 20 years, founded EXi along with her husband Lewis, also a physio, after realising that exercise was not being properly considered in the treatment of chronic disease.

Carron Manning EXi hero
Carron Manning, Co-founder and clinical director, EXi

“I’ve been prescribing exercise for a long time, for people with all types of illnesses, injuries, all the way up to elite athletes – the full spectrum,” she says. “And we could see that there was a huge gap in terms of medicine for people with chronic diseases like diabetes, heart disease, hypertension and cancer. These people are managed primarily through drugs and medical based treatments, whereas the reasons that they are in that situation in the first place are often due to their lifestyle, diet, lack of activity, and a few other factors. But all of that is not really being addressed.”

Targeting chronic disease

The Mannings realised there was potentially a huge opportunity to target chronic disease with exercise, but that most doctors and general practitioners simply don’t have the training in physical activity to effectively prescribe it.

“We could see that technology was really starting to catch up with where we needed it to be,” she says. “So we thought we could actually do something about it, we could put everything together to make an intelligent, automated system based on medical guidelines. It had to be entirely robust and evidence-based, because clinicians will throw things out immediately if they aren’t evidence based – as I would.”

After spending around a year researching and developing a system, the company put together the first iteration of its app, which received positive feedback from Harvard University and ukactive in 2016.

“People could see that we were different, because it was the first app to do this,” says Manning.

Grace McNamara
Grace McNamara, CEO, EXi

The company then spent some years refining the product and building out its team, including bringing on board Grace McNamara as CEO, who joined from Apple where she led the company’s health and fitness strategic initiatives in Europe and the Middle East.

Prescribing exercise like drugs

Fast forward to today, and the company has a robust, clinically validated app that tracks a wide range of metrics to deliver fully automated, highly personalised exercise programmes. With both iOS and Android apps, EXi can draw data from almost any wearable that puts data into Apple HealthKit or Google Fit.

“We are prescribing exercise in the same way as a doctor prescribes drugs, specifically for therapeutic purposes, to both help prevent and manage medical conditions,” says Manning. “We know, for example, that exercise will have a profound effect on blood pressure, on circulation, it helps to prevent certain types of cancer. This is the impact of exercise – no drug has ever been created, which has the same molecular or physiological effect as exercise.”

EXi’s programmes are based on the principle of exercise intensity. Working at the correct intensity level is key to enabling people with chronic conditions to exercise safely and to ensure they are getting the maximal health benefits.

“We know there’s a specific dose response with exercise, so we know exactly what the effects will be for any given population based on research,” says Manning. “We know how hard to push somebody safely, we know how effective it’s going to be on their medical condition. And we’ve done this for any combination of 23 medical conditions.”

Patients can download the app themselves to get started, but clinicians also have access via a dashboard where they can view all their patients in a single view. Health outcome measures are tracked on a weekly basis, including a GPS-enabled six minute walking test, resting heart rate, blood pressure, waist circumference, and BMI.

Proving the impact

EXi is currently engaged in research projects with University College London, King’s College and others to prove its effectiveness and impact on patients’ lives, but also the potential economic impact. The app is free for patients and is currently available to healthcare providers at a nominal cost, while EXi works to prove that it can “fundamentally shift the needle on care delivery”.

While currently targeting some of the key national NHS frameworks in the UK, EXi also expects to enter the US market later this year or next, with the national Medicare and Medicaid programmes likely to be a key focus.

“One of our fundamentals is that everyone should have access to healthcare, and I think that ‘get healthy, get active’ is a statement that everyone should hear and be able to get a prescription for that regardless of their status,” says Manning.

To date, EXi has raised around £1.5 million in angel funding, and expects it will need to raise another £1.5 – £2 million by the end of the year or early next year.

Images courtesy of EXi
Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Omecu aims to reduce analysis time and democratise genome data

Spinout company aims to revolutionise the handling of genome data by drastically reducing the time it takes to analyse millions of genetic records. Omecu Ltd,...

Machine learning robots a step in the right direction for tetraplegic patients

Machine learning enables thought-controlled robots that learn from mistakes. Two Ecole Polytechnique Fédérale de Lausanne (EPFL) research groups teamed up to develop a machine learning...

Abbott launches Lingo longevity wearable with continuous ketone tracking

Abbott pushes the envelope of biowearables as it announces its new tech for tracking ketones biomarkers. Abbott, the company behind the Freestyle Libre continuous glucose...

    Subscribe to our newsletter